Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Código da empresaARCT
Nome da EmpresaArcturus Therapeutics Holdings Inc
Data de listagemMay 22, 2013
CEOPayne (Joseph E)
Número de funcionários174
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 22
Endereço10285 Science Center Drive
CidadeSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92121-1132
Telefone18589002660
Sitehttps://arcturusrx.com/
Código da empresaARCT
Data de listagemMay 22, 2013
CEOPayne (Joseph E)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados